Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 16, 2016 - Issue 8
Submit an article Journal homepage
1,667
Views
2
CrossRef citations to date
0
Altmetric
Editorial

First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?

Antonio PassaroDivision of Thoracic Oncology, European Institute of Oncology, Milan, ItalyCorrespondence[email protected]
View further author information
,
Gianluca SpitaleriDivision of Thoracic Oncology, European Institute of Oncology, Milan, ItalyView further author information
&
Filippo de MarinisDivision of Thoracic Oncology, European Institute of Oncology, Milan, ItalyView further author information
Pages 799-801 | Received 09 May 2016, Accepted 04 Jul 2016, Published online: 15 Jul 2016

References

  • Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Nal Compr Canc Netw. 2012;10:1236–1271.
  • Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol. 2012;19:S52–S58.
  • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
  • Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. 2014 Sep;15(4):244.
  • Passaro A, Gori B, de Marinis F. Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. J Thorac Dis. 2013;5(4):383–384. doi:10.3978/j.issn.2072-1439.2013.07.32.
  • Passaro A, Pochesci A, Spitaleri G, et al. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7? J Thorac Dis. 2016;8(3):E217–E220.
  • Rosell R. What new therapeutic targets exist for EGFR-mutant NSCLC? Lancet Oncol. 2014 Oct;15(11):1184–1185.
  • Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 1;20(7):2001–2010.
  • Hall RD, Le TM, Haggstrom DE, et al. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015 Oct;4(5):515–523.
  • Xiong A, Yang Z, Shen Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel). 2014 Apr 16;6(2):926–957.
  • Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3:422–433.
  • de Marinis F, Bria E, Ciardiello F, et al. International experts panel meeting of the italian association of thoracic oncology on anti-angiogenetic drugs for non-small-cell lung cancer: realities and hopes. J Thorac Oncol. 2016;11:1153–1169. doi:10.1016/j.jtho.2016.03.015.
  • Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244.
  • Stahel RA, Dafni U, Gautschi O, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. Presented at: 2015 European Cancer Congress; 2015 Sep 25–29; Vienna. Abstract 3BA.
  • Gridelli C, Rossi A, Ciardiello F, et al. BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab + erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced non-squamous non-small cell lung cancer. Clin Lung Cancer. 2016. doi:10.1016/j.cllc.2016.04.001.
  • Zhou C, Yao LD. Strategies to improve outcomes of patients with EGRF-mutant non-small cell lung cancer: review of the literature. J Thorac Oncol. 2016 Feb;11(2):174–186.
  • Tan C-S, Cho B-C, Soo RA. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer. 2016;93:59–68.
  • Ramalingam S, Rukazenkov Y, Thomas K, et al. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol. 2015;33(suppl; abstr TPS8102).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.